Patients with relapsed/refractory hairy-cell leukemia

Area of Science:

• Hematology
• Oncology
• Clinical Research

Background:

• Hairy cell leukemia (HCL) is a rare B-cell neoplasm with a generally good prognosis.
• Established first and second-line treatments include purine nucleoside analogues (PNAs) and rituximab.
• Limited options existed for patients experiencing multiple relapses.

Purpose of the Study:

• To evaluate the efficacy and outcomes of third and fourth-line therapies in HCL patients.
• To analyze real-world data on treatment response, survival, and relapse rates in relapsed HCL.

Main Methods:

• Retrospective analysis of 49 HCL patients with at least two relapses from a French cohort (1980-2011).
• Assessment of hematological response, relapse-free survival (RFS), and overall survival (OS) after third (L3) and fourth (L4) line therapies.
• Evaluation of treatment strategies, including PNAs and rituximab, and associated toxicities.

Main Results:

• High overall hematological response rates (OHRR) were observed: 97% after L3 and 94% after L4.
• Median RFS after L3 was 104 months; median OS was 235 months.
• Patients experienced frequent relapses, with shorter intervals between treatments as lines increased, and notable toxicities, including secondary cancers.

Conclusions:

• Third and fourth-line therapies achieve high response rates in relapsed HCL.
• Frequent relapses and treatment-related toxicities highlight the need for novel therapeutic strategies.
• Further research into innovative treatments is crucial for improving outcomes in multiply relapsed HCL.